PF092
Fas Ligand Plus, Human, Recombinant
Fas Ligand Plus, Human, Recombinant, consists of amino acids 103-281 fused to a 26-amino acid linker and FLAG®-tag at the N-terminus and expressed in HEK293 cells.
recombinant
expressed in HEK 293 cells
assay
≥95% (SDS-PAGE)
form
lyophilized
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, avoid repeated freeze/thaw cycles
shipped in
wet ice
storage temp.
−20°C
Quality Level
General description
Recombinant, human Fas ligand (amino acids 103-281) fused to a 26-amino acid linker and FLAG®-tag at the N-terminus and expressed in HEK293 cells. Glycosylation of recombinant human sFasL is similar or identical to natural human FasL. The molecular weight is ~32 kDa (nonglycosylated) and ~37-42 kDa (glycosylated) by SDS-PAGE under reducing conditions. The recombinant protein is produced in HEK293 cells. It does not require enhancer for activity. Useful for cytotoxicity assays.
Fas Ligand (FasL/APO-1L/CD95L) is a ~37-42 kDa type II transmembrane protein belonging to the TNF family. Interaction between FasL and Fas induces apoptosis of Fas-sensitive cells. FasL is implicated in CTL-mediated-killing, activation-induced cell death, creation of immune-privileged sites and tissue homeostasis. The extracellular domain of human FasL can be cleaved off by a metalloprotease, generating soluble FasL (sFasL). Circulating sFasL can be detected in serum of patients with melanoma and certain types of lymphoma.
Fas Ligand (FasL/APO-1L/CD95L) is a ~37-42 kDa type II transmembrane protein belonging to the TNF family. Interaction between FasL and Fas induces apoptosis of Fas-sensitive cells. FasL is implicated in CTL-mediated-killing, activation-induced cell death, creation of immune-privileged sites and tissue homeostasis. The extracellular domain of human FasL can be cleaved off by a metalloprotease, generating soluble FasL (sFasL). Circulating sFasL can be detected in serum of patients with melanoma and certain types of lymphoma.
Biochem/physiol Actions
≥1 ng/ml kills Fas-sensitive cells
Physical form
Lyophilized from PBS.
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Reconstitute in 50 µl PBS to yield a final stock concentration of 100 µg/ml. Further dilute in culture medium with 5% FCS immediately prior to use.
Other Notes
Ashkenazi, A., and Dixit, V.M. 1998. Science281, 1305.
Nagata, S., 1997 Cell88, 355.
Hahne, M., et al. 1996. Science274, 1363.
Bellgrau, D., et al. 1995. Nature377, 630.
Lowin, B., et al. 1994. Nature370, 650.
Russell, J.H., et al. 1993. Proc. Natl. Acad. Sci. USA90, 4409.
Nagata, S., 1997 Cell88, 355.
Hahne, M., et al. 1996. Science274, 1363.
Bellgrau, D., et al. 1995. Nature377, 630.
Lowin, B., et al. 1994. Nature370, 650.
Russell, J.H., et al. 1993. Proc. Natl. Acad. Sci. USA90, 4409.
Glycosylation of recombinant human sFasL is similar or identical to natural human FasL. The molecular weight is ~32 kDa (nonglycosylated) and ~35 kDa (glycosylated) by SDS-PAGE under reducing conditions. The recombinant protein is produced in HEK293 cells. It does not require enhancer for activity.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
FLAG is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持